

1 **Title: Decline of SARS-CoV-2 specific IgG, IgM and IgA in convalescent COVID-19 patients**  
2 **within 100 days after hospital discharge**

3 Huan Ma<sup>1,2#</sup>, Dan Zhao<sup>2#</sup>, Weihong Zeng<sup>1,2#</sup>, Yunru Yang<sup>2</sup>, Xiaowen Hu<sup>3</sup>, Peigen Zhou<sup>4</sup>, Jianping Weng<sup>1,5,6</sup>,  
4 Linzhao Cheng<sup>7</sup>, Xueying Zheng<sup>1,5,6\*</sup>, Tengchuan Jin<sup>1,2,8\*</sup>

5 <sup>1</sup>the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and  
6 Technology of China, Hefei, Anhui 230001, China

7 <sup>2</sup>Hefei National Laboratory for Physical Sciences at Microscale, Laboratory of Structural Immunology, CAS Key  
8 Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of  
9 Science and Technology of China, Hefei, Anhui 230027, China

10 <sup>3</sup>Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of USTC, Division of Life  
11 Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China

12 <sup>4</sup>Department of Statistics, University of Wisconsin-Madison, Madison, WI 53706, USA

13 <sup>5</sup>Joint Laboratory of Public Health, University of Science and Technology of China and Health Commission  
14 of Anhui Province, Hefei Anhui 230026, China

15 <sup>6</sup>Clinical Research Hospital (Hefei) of Chinese Academy of Science, Hefei Anhui 230001, China

16 <sup>7</sup>Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei Anhui 230026,  
17 China, and Johns Hopkins University School of Medicine, Baltimore, MD USA

18 <sup>8</sup>CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Science, Shanghai 200031, China

19

20 **\*To whom correspondence should be addressed:**

21 Prof. Tengchuan Jin (primary contact): Division of Life Sciences and Medicine, University of Science and  
22 Technology of China, Hefei, 230027, China; Email: jint@ustc.edu.cn; Tel: +86-551-63600720;

23 Prof. Xueying Zheng: the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of  
24 Science and Technology of China, Hefei, Anhui 230001, China; Email: lxyzheng@ustc.edu.cn; Tel:  
25 +86-551-62264206

26

27 **#These authors contributed equally to this work.**

28

29 **Abstract**

30 Monitoring the levels of SARS-CoV-2 specific antibodies such as IgG, M and A in COVID-19 patient is  
31 an alternative method for diagnosing SARS-CoV-2 infection and an simple way to monitor immune  
32 responses in convalescent patients and after vaccination. Here, we assessed the levels of  
33 SARS-CoV-2 RBD specific antibodies in twenty-seven COVID-19 convalescent patients over 28-99  
34 days after hospital discharge. Almost all patient who had severe or moderate COVID-19 symptoms and  
35 a high-level of IgG during the hospitalization showed a significant reduction at revisit. The remaining  
36 patients who had a low-level IgG during hospitalization stayed low at revisit. As expected, IgM levels in  
37 almost all convalescent patients reduced significantly or stayed low at revisit. The RBD-specific IgA  
38 levels were also reduced significantly at revisit. We also attempted to estimate decline rates of  
39 virus-specific antibodies using a previously established exponential decay model of antibody kinetics  
40 after infection. The predicted days when convalescent patients' RBD-specific IgG reaches to an  
41 undetectable level are approximately 273 days after hospital discharge, while the predicted decay  
42 times are 150 days and 108 days for IgM and IgA, respectively. This investigation and report will aid  
43 current and future studies to develop SARS-CoV-2 vaccines that are potent and long-lasting.

44

## 45 **Introduction**

46 The 2019 novel coronavirus (later renamed as SARS-CoV-2 in February 2020) infected over 12 million  
47 people globally by early July and caused mild to severe COVID-19 patients in millions. Monitoring the  
48 levels of antibodies such as immunoglobulin (Ig) G, M and A that are specific to SARS-CoV-2 and  
49 present in blood provides not only an alternative method for diagnosing SARS-CoV-2 infection  
50 (including asymptomatic carriers), but also an simple way to monitor immune responses in  
51 convalescent patients or after vaccination. A high and persistent level of SARS-CoV-2 specific  
52 antibodies, especially those that can bind to and neutralize the virus, would be a strong indication that  
53 an immunized host could resist to SRAS-CoV-2 infection. Currently, there are no effective drugs to  
54 specifically prevent or cure SARS-CoV-2 infection; therefore, host immune responses and  
55 antibody-based therapeutics will continue playing important roles in combating and later preventing  
56 COVID-19.

57

58 We previously established a set of diagnostic kits that quantitatively and sensitively measure the levels  
59 of serum IgG, IgM and IgA specific to the SARS-CoV-2 spike protein receptor binding domain (RBD),  
60 based on a cohort of 87 hospitalized COVID-19 patients and 483 negative controls (Ma et al., 2020).  
61 These antibodies specifically bind to the RBD may block its interaction with a cell-surface protein ACE2  
62 that serves as a main viral receptor. Previous studies demonstrated that the serum level of IgG that  
63 specifically binds to the RBD highly correlates with that of neutralizing antibody activity in blocking  
64 infection of SARS-CoV-2 or a pseudo-virus (Ni et al., 2020; Robbiani et al., 2020; Wu et al., 2020). Our  
65 RBD-specific, chemiluminescence-based kits are highly quantitative and sensitive for detecting  
66 SARS-CoV-2 elicited IgA, IgG and IgM in blood (Ma et al., 2020). During the optimal detection  
67 window of 16-25 days post illness onset, levels of RBD-specific IgA and IgG, but not IgM, were  
68 significantly higher in severe and moderate than mild COVID-19 patients (Ma et al., 2020).

69

## 70 **Results and Discussions**

71 To assess the levels of SARS-CoV-2 specific antibodies in COVID-19 convalescent patients over time  
72 after hospital discharge, we used the same kits for detecting RBD-specific IgG, IgM and IgA levels in  
73 blood of patients in this cohort as we did for them during the hospitalization(Ma et al., 2020).  
74 Thirty-three convalescent patients living in Anhui Province of China voluntarily came back to our clinic  
75 for revisit, 28-99 days after hospital discharge. Six of them were detected positive for SARS-CoV-2  
76 nucleic acids and excluded in the current serology study. The information of 27 qualified  
77 convalescent patients is listed in **Supplemental table 1** in the order of COVID-19 severity during  
78 hospitalization. The table includes clinical information, discharge and revisit dates, and interval (28-99  
79 days with a median 91 days) for each patient. The levels of the RBD-specific serum IgG, IgM and IgA  
80 (measured as relative light unit or RLU after 40-times dilution) shortly before discharge and at revisit  
81 are tabulated at **Supplemental Table 2**. In **Figure 1 (A-C)**, we plotted antibody levels soon before  
82 discharge and at revisit as Cutoff Index (COI), which is the ratio of RLU Signal / Cutoff value  
83 determined previously for serum IgG, IgM and IgA, respectively(Ma et al., 2020). Among the 27  
84 convalescent patients, all (except #10) who had severe or moderate COVID-19 symptoms and a  
85 high-level of IgG during the hospitalization showed a significant reduction at revisit (**A**). The  
86 remaining patients who had a low-level IgG during hospitalization stayed low at revisit. As expected,  
87 IgM levels in these convalescent patients reduced significantly or stayed low at revisit, except #14 (**B**).  
88 The RBD-specific IgA levels were also reduced significantly at revisit (**C**), except patient #10 who also  
89 had an increased IgG, but not IgM. Few exceptional cases will need further studies.

90

91 We also attempted to estimate decline rates of virus-specific antibodies using a previously established  
92 exponential decay model of antibody kinetics after infection(Teunis et al., 2016). Based on the  
93 combined data of COI ratios before and after discharge for each of the 27 patients, we plotted decay  
94 curves for RBD-specific IgG, IgM and IgA over time (**Figure 1D-F**). The predicted days when  
95 convalescent patients' RBD-specific IgG reaches to an undetectable level are approximately 273 days  
96 (ranging from 134-304 days or 4.5-10 months) after hospital discharge (**D**), while the predicted decay  
97 times are 150 days and 108 days for IgM and IgA, respectively.

98

99 In summary, the initial data of this longitudinal study showed that the levels of SARS-CoV-2  
100 RBD-specific antibodies in most COVID-19 convalescent patients reduced significantly or remained  
101 low within the first 100 days after discharge. A mathematical modeling and extrapolation predicts that  
102 the virus-specific IgG in this group of convalescent patients will disappear in 273 days (~ 9 months).  
103 Our data and analyses provide timely and critical information on how long acquired humoral immune  
104 responses to this new human coronavirus could persist. In literature, there are so far few papers on  
105 the persistence of the SARS-CoV-2 elicited antibodies after recovery beyond two weeks(Long et al.,  
106 2020; Ni et al., 2020; Robbiani et al., 2020; Wu et al., 2020). In one study, blood samples (both cells  
107 and plasma) of six convalescent patients were collected two weeks after discharge and used to  
108 examine humoral and cellular immune responses(Ni et al., 2020). In another study (Wu et al., 2020),  
109 the serum IgG specific to the SARS-CoV-2 RBD and virus-neutralizing antibodies remained similarly  
110 low in 47 recovered patients two weeks after discharge. However, a recent study reported drastic  
111 declines of RBD-specific IgG and virus-neutralizing activities in 148 convalescent patients after an  
112 average of 39 days (Robbiani et al, 2020). The most recent study reported that 12.9% of the  
113 symptomatic group and 40% of the asymptomatic group became negative for IgG after 8 weeks,  
114 consistent with our findings of up to 99 days or 14 weeks.

115

116 Our current and other related studies point out a conclusion that SARS-CoV-2 infection did not elicit a  
117 long-last humoral immune memory. Similar to what reported with the SARS-CoV-1 infection (Cao et al.,  
118 2007). Our observation and decline kinetics modeling provide a guideline for SARS-CoV-2 vaccine  
119 designing as how to achieve long-last humoral immune response and memory. One way is to seek  
120 immunogens and adjuvants that show very strong immune responses such as virus-specific IgG  
121 induction that can be easily monitored. For example, a recent clinical trial showed that an  
122 experimental vaccine using inactivated SARS-CoV-2 viruses with alum as the adjuvant only elicited  
123 comparable to, but not much higher virus-specific IgG production than what we and others observed in  
124 hospitalized COVID-19 patients (Xia et al., 2020). Using more potent immunogens and adjuvants to

125 enhance immune responses for stronger SARS-CoV-2 IgG production will be an important early  
126 indication for effective development of SARS-CoV-2 vaccines that are highly potent and long-lasting.  
127 Although long-term data beyond 99 days after discharge are still in progress and needed to confirm our  
128 modeling, our current report provides timely information and fills the gap of knowledge to assess the  
129 persistence of antibody levels in response to this novel human coronavirus. A rapid reduction of  
130 antibodies (IgG, IgM and IgA) specific to SARS-CoV-2 we observed in convalescent patients examined  
131 4-14 weeks after discharge warrants timely and close attention; however, one shall interpret our  
132 current data cautiously. First, we had data so far from a relatively small group of COVID-19  
133 convalescent patients, who were first chosen because we can compare changes of the virus-specific  
134 antibodies after discharge. Second, we measured only the antibodies specific to SARS-CoV-2 RBD  
135 in the study subjects. Third, we have not examined cellular immune responses in this cohort of  
136 patients as did by others (Grifoni et al., 2020; Ni et al., 2020). Overall, our data are similar to what  
137 reported with SARS-CoV-1 infection: patients recovered from SARS had a rapid IgG decline and  
138 became undetectable after 3 years (Cao et al., 2007). However, a study reported the presence of  
139 long-lasting memory T cells reactive to the SARS-CoV-1 N protein in SARS patients recovered from 17  
140 years ago (Le Bert et al., 2020). Nonetheless, our observational and longitudinal serology study  
141 provides timely and valuable information to aid current and future studies, to address important issues  
142 such as how to use convalescent plasma or hyper-immunoglobins to treat COVID-19 patients and how  
143 to develop SARS-CoV-2 vaccines that are highly potent and long-lasting.

144

## 145 **Funding**

146 T.J. is supported by the Strategic Priority Research Program of the Chinese Academy of Sciences  
147 (XDB29030104), National Natural Science Fund (Grant No.: 31870731 and U1732109), the  
148 Fundamental Research Funds for the Central Universities (WK2070000108). TJ is supported by a  
149 COVID-19 special task grant supported by Chinese Academy of Science Clinical Research Hospital  
150 (Hefei) with Grant No. YD2070002017. M.H. is supported by the new medical science fund of USTC

151 (WK2070000130). JW and XY are supported by the Fundamental Research Funds for the Central  
152 Universities with Grant No. YD9110004001 and YD9110002002, respectively.

153

#### 154 **Acknowledgements**

155 We thank the staff and patients in The First Affiliated Hospital of USTC for their support in providing  
156 samples and clinical data collection. We would also like to thank Profs. Tian Xue and other colleagues  
157 in Division of Life Sciences and Medicine for their generous and professional support.

158

#### 159 **Conflict of Interest Disclosures**

160 Authors declare that they have no conflicts of interest.

161

162

163

164 **References**

- 165 Cao, W.C., Liu, W., Zhang, P.H., Zhang, F., and Richardus, J.H. (2007). Disappearance of antibodies to  
166 SARS-associated coronavirus after recovery. *N Engl J Med.* 2007;357(11):1162-1163.  
167 doi:10.1056/NEJMc070348.
- 168 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A.,  
169 Sutherland, A., Premkumar, L., Jadi, R.S., *et al.* (2020). Targets of T Cell Responses to SARS-CoV-2  
170 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell.*  
171 2020;181(7):1489-1501.e15. doi:10.1016/j.cell.2020.05.015.
- 172 Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y., Lin, M., Tan,  
173 N., Linster, M., *et al.* (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS,  
174 and uninfected controls. *Nature.* 2020;10.1038/s41586-020-2550-z. doi:10.1038/s41586-020-2550-z.
- 175 Long, Q.X., Tang, X.J., Shi, Q.L., Li, Q., Deng, H.J., Yuan, J., Hu, J.L., Xu, W., Zhang, Y., Lv, F.J., *et al.*  
176 (2020). Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature*  
177 *medicine.* 2020;26(8):1200-1204. doi:10.1038/s41591-020-0965-6.
- 178 Ma, H., Zeng, W., He, H., Zhao, D., Jiang, D., Zhou, P., Cheng, L., Li, Y., Ma, X., and Jin, T. (2020).  
179 Serum IgA, IgM, and IgG responses in COVID-19. *Cell Mol Immunol.* 2020;17(7):773-775.  
180 doi:10.1038/s41423-020-0474-z.
- 181 Ni, L., Ye, F., Cheng, M.L., Feng, Y., Deng, Y.Q., Zhao, H., Wei, P., Ge, J., Gou, M., Li, X., *et al.* (2020).  
182 Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent  
183 Individuals. *Immunity.* 2020;52(6):971-977.e3. doi:10.1016/j.immuni.2020.04.023.
- 184 Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C.C., Wang, Z., Cho, A., Agudelo, M., Barnes,  
185 C.O., Gazumyan, A., Finkin, S., *et al.* (2020). Convergent antibody responses to SARS-CoV-2 in  
186 convalescent individuals. *Nature.* 2020;10.1038/s41586-020-2456-9. doi:10.1038/s41586-020-2456-9.
- 187 Teunis, P.F., van Eijkeren, J.C., de Graaf, W.F., Marinović, A.B., and Kretzschmar, M.E. (2016). Linking  
188 the seroresponse to infection to within-host heterogeneity in antibody production. *Epidemics.*  
189 2016;16:33-39. doi:10.1016/j.epidem.2016.04.001.
- 190 Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., *et al.* (2020).  
191 Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their  
192 implications. *medRxiv*, 2020.03.30.20047365; doi: <https://doi.org/10.1101/2020.03.30.20047365>.
- 193 Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., *et al.*  
194 (2020). Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity  
195 Outcomes: Interim Analysis of 2 Randomized Clinical Trials. *JAMA.* 2020;10.1001/jama.2020.15543.  
196 doi:10.1001/jama.2020.15543.

197


198

199

200 **Figure legend**

201 **Figure 1** Changes of SARS-CoV-2 RBD-specific serum IgG, IgM and IgA levels in 27 convalescent  
202 patients near hospital discharge and at revisit 28-99 days after discharge. **(A-C)** The antibody levels  
203 are presented as Cut-Off Index (COI) which is calculated as RLU signal divided by the Cut-Off value  
204 previously set for each of IgG, IgM and IgA, respectively. The p values for the difference between  
205 discharge and revisit are  $< 0.0001$ ,  $0.0023$  and  $0.0020$  for IgG, IgM and IgA, respectively. **(D-F)** Decline  
206 curves for RBD-specific IgG (D), IgM (E) and IgA (F) over time, based on a mathematical model of  
207 exponential decay after its peak at recovery (soon before or at discharge). The ratios of COI at  
208 revisit versus discharge (day 0) is plotted by  $\log_{10}$  scale for each patient's IgG, IgM and IgA separately,  
209 as a function of time (days after discharge). See more details in supplemental Methods. The decay  
210 curve is marked as a blue line, and 95% confidence interval is marked as a grey zone for each type of  
211 SARS-CoV-2 specific antibodies.

212



**Figure 1**